GLP1R and diabetic kidney disease: Treatment with GLP1-RA or SGLT2i significantly improved RRI independently of changes in e-GFR and albuminuria, suggesting that RRI monitoring may be a useful and simple tool to follow the evolution of DKD and the effects of therapy on renal outcomes, before changes in e-GFR and albuminuria occur.